- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00006249
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma.
PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
- Compare the effect of adjuvant therapy with pegylated interferon alfa vs observation, in terms of distant metastases-free survival, in patients with previously resected stage III melanoma.
- Compare the overall survival in these patients after treatment with pegylated interferon alfa vs observation.
- Determine the toxicity of pegylated interferon alfa in these patients.
- Determine the compliance of these patients treated with pegylated interferon alfa.
- Compare the quality of life in these patients after treatment with pegylated interferon alfa vs observation.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to type of nodal involvement (N1 vs N2), number of positive nodes (1 vs 2-4 vs 5 or more vs not assessed), Breslow primary (T1-2 vs T3 vs T4 vs unknown), ulceration of primary tumor (absent vs present vs unknown), sex, and center. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive pegylated interferon alfa subcutaneously weekly for 5 years.
- Arm II: Patients undergo observation only. Treatment continues in the absence of distant metastases or unacceptable toxicity.
Quality of life is assessed at baseline, and then at months 3, 12, 24, 36, 48, and 60.
Patients are followed every 6 months for 5 years.
PROJECTED ACCRUAL: A total of 1,200 patients (600 per treatment arm) will be accrued for this study within 1.5-2 years.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Berlin, Allemagne, D-13122
- Robert Roessle Klinik
-
Bochum 1, Allemagne, D-44791
- Saint Josef Hospital
-
Dortmund, Allemagne, 44123
- Stadt. Kliniken
-
Erlangen, Allemagne, D-91054
- Universitaet Erlangen
-
Goettingen, Allemagne, D-37075
- Georg August Universitaet
-
Hamburg, Allemagne, D-22765
- Haematologisch-Onkologische Praxis Altona
-
Heidelberg, Allemagne, D-69115
- Universitaets-Hautklinik Heidelberg
-
Leipzig, Allemagne, D-04103
- Universitaet Leipzig - Chirurgische Klinik und Poliklinik I
-
Magdeburg, Allemagne, D-39120
- Otto - Von - Guericke - Universitaet Magdeburg
-
Mannheim, Allemagne, D-68135
- Klinikum der Stadt Mannheim
-
Wuerzburg, Allemagne, D-97080
- Universitaet Wuerzburg/Hautkrankheiten
-
-
-
-
-
Newcastle, Australie, NSW 2300
- David Maddison Clincial Sciences
-
-
Victoria
-
East Melbourne, Victoria, Australie, 8006
- Peter MacCallum Cancer Institute
-
Heidelberg West, Victoria, Australie, 3081
- Austin and Repatriation Medical Centre
-
-
Western Australia
-
Perth, Western Australia, Australie, 6000
- Royal Perth Hospital
-
Perth, Western Australia, Australie, 6009
- Sir Charles Gairdner Hospital, Perth
-
-
-
-
-
Brussels, Belgique, 1200
- Cliniques Universitaires Saint-Luc
-
Brussels, Belgique, 1000
- Institut Jules Bordet
-
Brussels, Belgique, 1070
- Hopital Universitaire Erasme
-
Edegem, Belgique, B-2650
- Universitair Ziekenhuis Antwerpen
-
Gosselies, Belgique, 6041
- Clinique Notre Dame de Grâce
-
Leuven, Belgique, B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Sofia, Bulgarie, 1756
- National Centre of Oncology
-
-
-
-
-
Zagreb, Croatie, 10000
- University Hospital Sestre milosrdnice
-
-
-
-
-
Madrid, Espagne, 28041
- Hospital Universitario 12 de octubre
-
Zaragoza, Espagne, 50009
- Hospital Clinico Universitario
-
-
-
-
-
Tallinn, Estonie, 11619
- North-Estonian Regional Hospital Cancer Centre
-
-
-
-
-
Amiens, France, 80054
- Centre Hospitalier Universitare d'Amens
-
Besancon, France, 25030
- CHR de Besancon - Hopital Saint-Jacques
-
Bordeaux, France, 33075
- Hopital Saint André
-
Boulogne Billancourt, France, F-92104
- CHU Ambroise Pare
-
Grenoble, France, 38043
- Chr De Grenoble - La Tronche
-
Lille, France, 59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Limoges, France, 87042
- Centre Hospital Regional Universitaire de Limoges
-
Lyon, France, 69373
- Centre LEON BERARD
-
Montpellier, France, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Montpellier, France, 34295
- Hopital St. Eloi
-
Nice, France, F-06202
- Hopital L'Archet - 2
-
Paris, France, 75018
- Hôpital Bichat - Claude Bernard
-
Paris, France, 75475
- Hôpital Saint-Louis
-
Pessac, France, 33604
- Hôpital Haut Lévêque
-
Reims, France, 51092
- Centre Hospitalier Universitaire
-
Rennes, France, 35042
- Centre Eugene Marquis
-
Saint Cloud, France, 92211
- Centre René Huguenin
-
Saint Priest en Jarez, France, 42277
- Centre Hospitalier Regional et Universitaire de Saint-Etienne
-
Strasbourg, France, 67091
- Hopitaux Universitaire de Strasbourg
-
Thionville, France, 57126
- Centre Hospitalier Regional Metz Thionville
-
Tours, France, 37044
- Centre Hospitalier Universitaire Bretonneau de Tours
-
Vandoeuvre-les-Nancy, France, 54511
- Centre Alexis Vautrin
-
Villejuif, France, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Haifa, Israël, 31096
- Rambam Medical Center
-
Holon, Israël, 58100
- Wolfson Medical Center
-
Tel-Aviv, Israël, 64239
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Aviano, Italie, 33081
- Centro di Riferimento Oncologico - Aviano
-
Firenze, Italie, I-50011
- Ospendale S.M. Annunziata-A.S.DI Firenze
-
Genoa (Genova), Italie, 16132
- Istituto nazionale Per la Ricerca sul Cancro
-
Milano, Italie, 20141
- European Institute of Oncology - Chemo Prevention
-
Milano (Milan), Italie, 20133
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
-
Naples, Italie, 80131
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
-
Rome, Italie, 00161
- Istituto Regina Elena
-
Torino, Italie, 10126
- Universita degli Studi di Torino
-
-
-
-
-
Lisbon, Le Portugal, 1099-023 Codex
- Instituto Portugues de Oncologia de Francisco Gentil - Centro de Lisboa
-
Porto, Le Portugal, 4200
- Instituto Portugues de Oncologia Centro do Porto, SA
-
-
-
-
-
Amsterdam, Pays-Bas, 1007 MB
- Vrije Universiteit Medisch Centrum
-
Leiden, Pays-Bas, 2300 CA
- Leiden University Medical Center
-
Nijmegen, Pays-Bas, NL-6500 HB
- University Medical Center Nijmegen
-
Rotterdam, Pays-Bas, 3075 EA
- Erasmus University Medical Center
-
Utrecht, Pays-Bas, 3584 CX
- Academisch Ziekenhuis Utrecht
-
-
-
-
-
Poznan, Pologne, 61 866
- Great Poland Cancer Center
-
Warsaw, Pologne, 02-781
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
-
-
-
-
-
Birmingham, Royaume-Uni, B29 6JD
- Selly Oak Hospital at University Hospital NHS Trust
-
Oxford, Royaume-Uni, OX3 7LJ
- Churchill Hospital
-
-
England
-
Bristol, England, Royaume-Uni, BS2 8ED
- Bristol Haematology and Oncology centre
-
Cambridge, England, Royaume-Uni, CB2 2QQ
- Addenbrooke's NHS Trust
-
Cheltenham, England, Royaume-Uni, GL53 7AN
- Cheltenham General Hospital
-
Exeter, England, Royaume-Uni, EX2 5DW
- Royal Devon and Exeter Hospital
-
Guildford, England, Royaume-Uni, GU2 5XX
- Royal Surrey County Hospital
-
Hull, England, Royaume-Uni, HU8 9HE
- Princess Royal Hospital
-
Leeds, England, Royaume-Uni, LS9 7TF
- St. James's Hospital
-
Leicester, England, Royaume-Uni, LE1 5WW
- Leicester Royal Infirmary
-
London, England, Royaume-Uni, SW3 6JJ
- Royal Marsden NHS Trust
-
London, England, Royaume-Uni, NW3 2QG
- Royal Free Hospital
-
London, England, Royaume-Uni, SW17 0QT
- St. George's Hospital
-
London, England, Royaume-Uni, EC1A 7BE
- Saint Bartholomew's Hospital
-
London, England, Royaume-Uni, SE1 9RT
- Guy's and St. Thomas' Hospitals NHS Trust
-
Merseyside, England, Royaume-Uni, CH63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne, England, Royaume-Uni, NE4 6BE
- Newcastle General Hospital
-
Salisbury, England, Royaume-Uni, SP2 8BJ
- Salisbury District Hospital
-
Sheffield, England, Royaume-Uni, S1O 2SJ
- Weston Park Hospital
-
Southampton, England, Royaume-Uni, SO16 6YD
- Southampton General Hospital
-
Sutton, England, Royaume-Uni, SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea, England, Royaume-Uni, SS0 0RY
- Southend NHS Trust Hospital
-
-
Northern Ireland
-
Belfast, Northern Ireland, Royaume-Uni, BT9 7AB
- Belfast City Hospital Trust
-
-
Scotland
-
Dundee, Scotland, Royaume-Uni, DD1 9SY
- Ninewells Hospital and Medical School
-
Glasgow, Scotland, Royaume-Uni, G11 6NT
- Western Infirmary
-
-
Wales
-
Cardiff, Wales, Royaume-Uni, CF4 7XL
- Velindre Cancer Center at Velinde Hospital
-
-
-
-
-
Prague (Praha), République tchèque, 128 08
- Charles University Hospital
-
-
-
-
-
Ljubljana, Slovénie, Sl-1000
- Institute of Oncology, Ljubljana
-
-
-
-
-
Aarau, Suisse, 5001
- Kantonspital Aarau
-
Bern, Suisse, CH-3010
- Inselspital, Bern
-
Chur, Suisse, CH-7000
- Ratisches Kantons und Regionalspital
-
Zurich, Suisse, CH-8091
- UniversitaetsSpital
-
-
-
-
-
Istanbul, Turquie, 34296
- Vakif Gureba Training Hospital
-
Izmir, Turquie, 35220
- Ege University Medical School
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Histologically confirmed previously resected stage III primary cutaneous melanoma or unknown primary with regional lymph node involvement
N1 disease
- Microscopic, nonpalpable nodal involvement
- Primary melanoma of any stage with clinically inapparent N1 regional lymph node metastases (T1-4, N1, M0) detected by elective lymph node dissection or sentinel node biopsy
N2 disease
- Palpable nodal involvement with synchronous primary melanoma or apparent nodal disease after prior excision (any pT, N2, M0)
- Regional lymph node recurrence at any interval after surgery for primary melanoma of any depth (T1-4, rN2, M0)
- Complete resection of primary melanoma with adequate surgical margins
- Full lymphadenectomy must be performed within 70 days of study
- No mucous membrane melanoma or ocular melanoma
- No evidence of distant or nonregional lymph node metastases or in transit metastases (even if previously resected)
- No incompletely resected disease due to gross extracapsular extension
PATIENT CHARACTERISTICS:
Age:
- 18 to 70
Performance status:
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- WBC at least 3,000/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin at least 9 g/dL
Hepatic:
- SGOT and SGPT less than 2 times upper limit of normal
- No active hepatitis
Renal:
- Creatinine less than 2.0 mg/dL
Cardiovascular:
No severe cardiovascular disease including the following:
- Arrhythmias requiring chronic treatment
- Congestive heart failure (New York Heart Association class III or IV)
- Symptomatic ischemic heart disease
Other:
- No other prior malignancy within the past 5 years except surgically cured nonmelanomatous skin cancer or carcinoma in situ of the cervix
- No thyroid dysfunction unresponsive to therapy
- No uncontrolled diabetes mellitus
- No active autoimmune disease
- No active and/or uncontrolled infection
- No history of neuropsychiatric disorder requiring hospitalization
- No known active alcohol or drug abuse
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior interferon alfa
- No prior immunotherapy for melanoma
- No other concurrent immunologic or biologic therapy
- No concurrent colony stimulating factors including epoetin alfa and filgrastim (G-CSF)
Chemotherapy:
- No prior chemotherapy for melanoma
- No concurrent chemotherapy
Endocrine therapy:
- No prior hormonal therapy for melanoma
- No concurrent hormonal therapy
- No concurrent chronic systemic corticosteroid therapy
Radiotherapy:
- No prior radiotherapy for melanoma
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from any prior recent surgery
Other:
- At least 30 days since other prior experimental therapy
- No other concurrent investigational drugs
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Aucune intervention: observation
5 years observation + 5 years follow up
|
|
Expérimental: pegylated interferon alfa
5 years pegylated interferon alfa + 5 years follow up
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
distant-metastasis free-survival (DMFS)
Délai: from randomization
|
distant-metastasis free-survival (DMFS) after randomization
|
from randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
survival
Délai: from randomization till death
|
duration of survival: time from randomization until death, whatever the cause
|
from randomization till death
|
toxicity
Délai: from randomization
|
toxicity
|
from randomization
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
quality of life
Délai: from randomization
|
Quality of life evaluation
|
from randomization
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: Alexander M. M. Eggermont, MD, PhD, Daniel Den Hoed Cancer Center at Erasmus Medical Center
Publications et liens utiles
Publications générales
- Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up. [Abstract] J Clin Oncol 29 (Suppl 15): A-8506b, 2011.
- Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12.
- Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7. doi: 10.1007/s00280-009-1072-z. Epub 2009 Jul 21.
- Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009 Jun 20;27(18):2916-23. doi: 10.1200/JCO.2008.20.2069. Epub 2009 May 11. Erratum In: J Clin Oncol. 2009 Sep 20;27(27):4630. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.
- Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer. 2009 Dec;45(18):3189-97. doi: 10.1016/j.ejca.2009.09.004. Epub 2009 Sep 28.
- Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, MacKie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-126. doi: 10.1016/S0140-6736(08)61033-8.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-8504, 473s, 2007.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs neuroendocrines
- Nevi et mélanomes
- Mélanome
- Effets physiologiques des médicaments
- Agents anti-infectieux
- Agents antiviraux
- Agents antinéoplasiques
- Facteurs immunologiques
- Interférons
- Interféron-alpha
Autres numéros d'identification d'étude
- EORTC-18991
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Mélanome (Peau)
-
Utah State UniversityActif, ne recrute pasTrouble d'excoriation (skin-picking)États-Unis
-
Karolinska InstitutetRegion StockholmComplétéTrichotillomanie | Trouble d'excoriation (skin-picking)Suède
Essais cliniques sur Thérapie adjuvante
-
Medical University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)RecrutementAccident vasculaire cérébral | Aphasie | Aphasie Non FluentÉtats-Unis
-
Columbia UniversityRésilié
-
NeuroTronik Inc.InconnueInsuffisance cardiaque | Insuffisance cardiaque aiguëParaguay
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale...ComplétéEn bonne santéSuisse
-
NeuroTronik Inc.InconnueInsuffisance cardiaque aiguëPanama
-
University of Roma La SapienzaComplétéÉchec de l'implant dentaire | Mucosite buccaleItalie
-
University of Alabama at BirminghamComplétéAccident vasculaire cérébral | Parésie du membre supérieur | AVC (Accident Cérébrovasculaire)États-Unis
-
Abbott Medical DevicesComplétéFibrillation auriculaire paroxystiqueAustralie, Allemagne, France, Italie, Le Portugal, Royaume-Uni
-
Abbott Medical DevicesComplétéFlutter auriculaire typiqueÉtats-Unis, Canada
-
Vyaire MedicalPas encore de recrutementSyndrome d'insuffisance respiratoire du nouveau-néItalie